Recreational salmon fishing resumes in California this weekend for limited time
Coastal salmon fishing was banned in 2023 and 2024 in an effort to help the population recover after years of declines. While commercial fishing remains canceled for a third consecutive year, fishery regulators recently decided to allow a limited season for recreational fishing on certain dates and with strict quotas.
'We're all very excited,' said William 'Captain Smitty' Smith, who was readying his charter fishing boat Riptide at Pillar Point Harbor in Half Moon Bay. 'There's a lot of buzz all around the harbor with everybody getting ready for it.'
Smith and his two deckhands have been buying bait and preparing hooks, nets and other gear to take 18 passengers fishing Saturday and Sunday. He said within hours of the April announcement that limited fishing would be allowed, 'my regulars all called and basically filled the boat.'
Smith is 71 and has been in the charter boat business for 50 years. The last time he was able to take passengers fishing for salmon was in 2022.
As his business has struggled during the last two years, he has turned to other types of outings to make ends meet, including fishing for rockfish, leading whale-watching trips and holding burials at sea where mourners scatter the ashes of loved ones.
He said anglers are 'chomping at the bit to go.' Each person will be allowed to catch up to two fish per day.
Read more: U.S. panel calls for suspending commercial salmon fishing in California for third year
The California Department of Fish and Wildlife is limiting ocean fishing under quotas in two windows in the summer and fall. The first is set to open Saturday-Sunday and allow for up to 7,000 salmon to be caught statewide.
If that number of fish isn't reached during the opening weekend, salmon fishing will be allowed until the limit is reached in subsequent stretches, which may include July 5-6, July 31-Aug. 3, and Aug. 25-31.
In addition to Half Moon Bay, fishing boats are expected to head out this weekend from other harbors in Central and Northern California such as Morro Bay, Santa Cruz, San Francisco, Bodega Bay and Fort Bragg.
'Given the 2-year ocean salmon fishery closure and the short duration of this fishing period, angler participation is expected to be high,' the department said in its announcement. 'Anglers should prepare for crowds and long wait times at public launch ramps and marinas and consider travel, parking, and launch ramp conditions when finalizing plans.'
The agency said fishing will reopen in the fall in some regions — including from Point Reyes in Marin County south to near Half Moon Bay, and from there to Point Sur in Big Sur — under a separate harvest limit guideline of 7,500 Chinook salmon.
The fishing industry depends on fall-run Chinook, which migrate upstream to spawn from July through December. For decades, government-run hatcheries in the Central Valley have reared and released millions of salmon each year to help boost their numbers.
Read more: Salmon populations are struggling, bringing economic woes for California's fishing fleet
Other salmon runs have suffered more severe declines. Spring-run Chinook are listed as threatened under the Endangered Species Act, and winter-run Chinook are endangered.
Biologists say salmon populations have declined because of a combination of factors including dams, which have blocked off spawning areas, the loss of vital floodplain habitats, and global warming, which is intensifying droughts and causing warmer temperatures in rivers.
During the severe 2020-22 drought, the water flowing from dams sometimes got so warm that it was lethal for salmon eggs. Although that drought was a major factor behind the declines in the salmon population, those who work in fishing also blame California's water managers and policies, saying too much water has been pumped to farms and cities, depriving rivers of sufficient cold water at the times salmon need it.
Smith said he hopes to see 'responsible water management' where state officials prioritize river flows for fish, as well as efforts to restore floodplains and improve hatchery operations.
Read more: 'A beautiful thing': Klamath River salmon are spotted far upstream in Oregon after dam removal
Because salmon typically feed in the ocean for about three years and then return to their natal streams, the decline in the numbers of surviving juvenile fish during the drought left a reduced population of adult fish. Scientists expect the population should improve somewhat next year because of the boost they received during 2023's historic wet winter, though they also caution that the situation facing California's salmon remains dire.
Smith said one change that has nurtured his hopes came last year, when the last of four dams were dismantled on the Klamath River in Northern California, enabling salmon to reach upstream spawning areas that had been sealed off for more than a century.
'I'm very hopeful for our future,' he said, adding that he is thinking about his 13-year-old grandson and the next generation.
'I want there to be a fishery for my grandson. I want him to be able to experience the thrill of catching a fish in the ocean.'
This story originally appeared in Los Angeles Times.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 hours ago
- Business Wire
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2025 and provided business updates. 'This quarter was defined by strong execution that is driving momentum across our business,' said Ian F. Smith, Interim Chief Executive Officer and Director of Stoke Therapeutics. 'Our Phase 1/2 and open-label extension studies have provided a strong foundational understanding of zorevunersen and support the EMPEROR Phase 3 registrational study design. We continue to generate long-term data that are helping us appreciate the disease modifying potential of zorevunersen. At the same time, we see growing awareness of Dravet syndrome as a severe neurodevelopmental disease, which is bringing attention to our work and a high degree of interest in zorevunersen.' Smith continued, 'Beyond Dravet, we have initiated clinical development in a second disease area, advancing STK-002 into a Phase 1 study in patients with Autosomal Dominant Optic Atrophy. Without any treatments approved for ADOA, patients are at risk of progressive loss of sight caused primarily by insufficient OPA1 protein levels. Our pre-clinical data support the potential for STK-002 to restore naturally-occurring protein expression to maintain or improve vision in these patients. We look forward to continuing to expand our approach into new disease areas where we believe we can deliver first-in-class, disease modifying medicines for severe genetic diseases.' Recent Program Highlights Yesterday, the Company announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Sites have been initiated in the U.S., UK, Japan and are planned for Europe. Today, the Company announced new positive findings from the long-term open-label extension (OLE) studies of zorevunersen in children and adolescents with Dravet syndrome. Substantial and durable reductions in convulsive seizure frequency on top of standard-of-care medicines were observed through three years of zorevunersen treatment. The data also demonstrate continued improvements in cognition and behavior during the 3-year OLE period beyond the initial 9 months of treatment in the Phase 1/2 studies. Today, the Company announced the Phase 1 study (OSPREY) of STK-002 in patients with Autosomal Dominant Optic Atrophy (ADOA) is now underway. In July, the Company presented data at the European Paediatric Neurology Society (EPNS) Congress from an analysis that evaluated the potential effects on cognition and behavior of a dosing regimen similar to the one now being evaluated in Phase 3. (For full details, see the press release). Upcoming Anticipated Milestones The Company plans to present additional data from the zorevunersen clinical development program at upcoming medical congresses in 2025. Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP-1 in 2026. SYNGAP-1 is a severe and rare genetic neurodevelopmental disease. Second Quarter 2025 Financial Results As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028. Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended June 30, 2025 was $10.6 million, compared to $4.8 million, for the same period in 2024. Revenue recognized from the License and Collaboration Agreement with Biogen for the three months ended June 30, 2025 was $3.2 million. There was no revenue for the same period in 2024. Net loss for the three months ended June 30, 2025 was $23.5 million, or $0.40 per share, compared to a net loss of $25.7 million, or $0.46 per share for the same period in 2024. Research and development expenses for the three months ended June 30, 2025 were $25.9 million, compared to $21.1 million for the same period in 2024. General and administrative expenses for the three months ended June 30, 2025 were $15.3 million, compared to $13.0 million for the same period in 2024. Year-to-Date 2025 Financial Results Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the six months ended June 30, 2025 was $16.8 million, compared to $9.0 million for the same period in 2024. Revenue recognized from the License and Collaboration Agreement with Biogen for the six months ended June 30, 2025 was $155.6 million. There was no revenue for the same period in 2024. Net income for the six months ended June 30, 2025 was $89.4 million, or $1.50 per diluted share, compared to a net loss of $52.1 million, or $1.02 per share, for the same period in 2024. Research and development expenses for the six months ended June 30, 2025 were $58.5 million, compared to $43.5 million for the same period in 2024. General and administrative expenses for the six months ended June 30, 2025 were $29.9 million, compared to $23.3 million for the same period in 2024. The increase in operating expenses for the three and six month periods ending June 30, 2025 over the same periods in 2024 primarily relate to increases in costs associated with an increase in personnel and launch readiness expense. Stoke Webcast and Conference Call for Analysts and Investors Stoke management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30pm Eastern Time. The webcast will be available on the Investors & News section of Stoke's website at Research analysts who plan to join the call and participate in the Q&A session may register here to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking here. A replay of the webcast will be archived and available for at least 90 days following the event. About Dravet Syndrome Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. More than 90 percent of patients continue to experience seizures despite treatment with the best available anti-seizure medicines. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan. 1 About Zorevunersen Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition, and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. About Autosomal Dominant Optic Atrophy (ADOA) Autosomal dominant optic atrophy (ADOA) is the most common inherited optic nerve disorder. It is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Severity can vary and the rate of vision loss can be difficult to predict. Roughly half of people with ADOA fail driving standards and up to 46% are registered as legally blind. More than 400 different OPA1 mutations have been reported in people diagnosed with ADOA. ADOA affects approximately one in 30,000 people globally with a higher incidence in Denmark of one in 10,000 due to a founder effect. Currently there is no approved treatment for people living with ADOA. About STK-002 STK-002 is a proprietary antisense oligonucleotide (ASO) in clinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Stoke believes that STK-002 has the potential to be the first disease-modifying therapy for people living with ADOA. An estimated 65% to 90% of cases are caused by mutations in the OPA1 gene, most of which lead to a haploinsufficiency resulting in 50% OPA1 protein expression and disease manifestation. STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene to restore OPA1 protein expression with the aim to maintain or improve vision in patients with ADOA. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-002. STK-002 has been granted orphan drug designation by the FDA as a potential new treatment for ADOA. A Phase 1 study (OSPREY) of STK-002 in patients with ADOA is now underway. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the Company's quarterly results and cash runway; its future operating results and current or future financial position and liquidity; the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the design, timing and results of clinical studies, data readouts, regulatory decisions and other presentations for zorevunersen and STK-002; the ability of STK-002 to treat the underlying causes of Autosomal Dominant Optic Atrophy (ADOA) and maintain or improve vision; our expectations, plans, aspirations and goals, including those related to the potential of zorevunersen and our collaborations with Biogen and Acadia. Statements including words such as 'anticipate,' 'expect,' 'plan,' 'will,' or 'may' and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, the Company would not obtain the anticipated financial or other benefits; the possibility that the Company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company's ability to protect its intellectual property; the Company's ability to fund development activities and achieve development goals through mid-2028; and the other risks and uncertainties described under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Reference: Based on Stoke Therapeutics' preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by . Financial Tables Follow Stoke Therapeutics, Inc. and subsidiary Consolidated balance sheets (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 101,472 $ 127,983 Marketable securities - current 146,236 88,916 Prepaid expenses 13,694 11,117 Restricted cash - current 75 75 Interest receivable 1,622 700 Other current assets 6,871 3,965 Total current assets $ 269,970 $ 232,756 Marketable securities - long-term 107,256 29,824 Restricted cash - long-term 721 721 Operating lease right-of-use assets 3,218 4,345 Property and equipment, net 3,343 3,909 Total assets $ 384,508 $ 271,555 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,313 $ 2,498 Accrued and other current liabilities 25,616 18,567 Deferred revenue - current portion 8,749 18,991 Total current liabilities $ 38,678 $ 40,056 Deferred revenue - net of current portion 9,632 — Other long term liabilities 1,255 2,478 Total long term liabilities 10,887 2,478 Total liabilities $ 49,565 $ 42,534 Stockholders' equity Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 54,723,455 and 54,032,826 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 5 5 Additional paid-in capital 736,276 719,997 Accumulated other comprehensive income (loss) 96 (151 ) Accumulated deficit (401,434 ) (490,830 ) Total stockholders' equity $ 334,943 $ 229,021 Total liabilities and stockholders' equity $ 384,508 $ 271,555 Expand Stoke Therapeutics, Inc. and subsidiary Consolidated statements of operations and comprehensive income (loss) (in thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 13,817 $ 4,831 $ 172,386 $ 9,048 Operating expenses: Research and development 25,855 21,136 58,531 43,504 General and administrative 15,262 13,037 29,915 23,258 Total operating expenses 41,117 34,173 88,446 66,762 Income (loss) from operations (27,300 ) (29,342 ) 83,940 (57,714 ) Other income (expense): Interest income (expense), net 3,789 3,695 6,678 6,121 Other income (expense), net 28 (48 ) 57 (476 ) Total other income (expense) 3,817 3,647 6,735 5,645 Income (loss) before income taxes $ (23,483 ) $ (25,695 ) $ 90,675 $ (52,069 ) Provision for income taxes — — 1,278 — Net income (loss) $ (23,483 ) $ (25,695 ) $ 89,397 $ (52,069 ) Net income (loss) per share: Basic $ (0.40 ) $ (0.46 ) $ 1.54 $ (1.02 ) Diluted (0.40 ) (0.46 ) $ 1.50 (1.02 ) Weighted-average common shares outstanding: Basic 58,353,855 55,765,948 $ 58,109,622 51,288,222 Diluted 58,353,855 55,765,948 $ 59,681,472 51,288,222 Comprehensive income (loss): Net income (loss) $ (23,483 ) $ (25,695 ) $ 89,397 $ (52,069 ) Other comprehensive gain (loss): Unrealized gain (loss) on marketable securities 200 (15 ) 247 9 Total other comprehensive gain (loss) $ 200 $ (15 ) $ 247 $ 9 Comprehensive income (loss) $ (23,283 ) $ (25,710 ) $ 89,644 $ (52,060 ) Expand
USA Today
19 hours ago
- USA Today
Gas prices are down from last year. Here's where they could head next.
July gas prices were down 2.2% from June and 9.5% from the year prior, according to the latest CPI report from the Labor Department. Why prices at the pump could continue to slip in the months ahead. While headline inflation held steady in July, tariffs appear to be hitting some imported goods like furniture and audio and video products, according to the latest consumer price index report from the Labor Department. One source of relief for consumers? Prices at the pump. The latest CPI report shows July prices were down 2.2% from June and 9.5% from the year prior. The national average for a gallon of regular unleaded as of Aug. 12 was $3.14, according to AAA, down from $3.44 a year ago. Prices could continue to slip in the months ahead as the weather cools and oil production ramps up. "Gas prices are lower than they were a year ago. That has really persisted this year and given some confidence to the consumer to feel a little bit more wealthy at a time when there's inflation everywhere else," said Matt Smith, an oil analyst with commodity data firm Kpler. "They're definitely providing, and should provide, a bit of a respite going forward." Gas prices 'steady' in 2025 The best way to describe gas prices so far this year? "Steady," especially when compared to recent years with dramatic swings like 2022, according to AAA spokesperson Aixa Diaz. "It's certainly good news for drivers," Diaz said. Increased output from oil producers has helped keep prices stable, with Brent crude – the world benchmark for oil prices – largely trading between roughly $60 and $70 per barrel in recent months. The group of oil-producing countries known as OPEC+ has hiked production to regain market share, according to Smith, and shows no signs of slowing after announcing plans to boost production again in September. Meanwhile, U.S. crude oil production hit record highs this year at more than 13 billion barrels per day, and smaller oil producers like Brazil and Guyana have also increased output. "We're seeing a lot of supply come to market to outpace demand, so that should weigh on gasoline prices," Smith said. Where does inflation stand? CPI report reveals inflation held steady in July as tariffs threatened wider impact How low will gas prices go? Gas prices could continue to fall in the months ahead if oil production remains elevated. The U.S. Energy Information Administration expects Brent crude oil prices to fall from an average $71 per barrel in July to $58 per barrel in the last three months of the year, then down to $50 per barrel in early 2026. Prices at the pump could also see relief as the weather cools and refineries switch from summer blends to cheaper winter blends. "I fully expect we'll see this drop from $3.15, where they're at now, to below the $3 per gallon mark," Smith said. "Probably into October. That's where we could really start to see a charge toward $2.50." But there are threats that could push prices higher. Hurricane season, for instance, hits its peak in September, driving up the risk for damage to U.S. refineries near the Gulf Coast. Geopolitical tensions could also affect prices. "If we do see (President Donald) Trump taking a harder line on trying to punish Russia and stop countries like India buying its crude, that could cause oil prices to rally," Smith said. "That's the biggest wild card for the oil market, and therefore gasoline prices."
Yahoo
a day ago
- Yahoo
Energy Domain Acquires Clerk Records, LLC and Proprietary Technology from Founder Jason Smith, Who Joins in Advisory Role
Joint Effort Will Integrate Structured, AI-extracted Courthouse Records into the Energy Domain Data Platform and Expand Standalone Product FORT WORTH, Texas, August 12, 2025--(BUSINESS WIRE)--Energy Domain, the Fort Worth-based technology company behind Energy Domain Marketplace and Energy Domain Data, announced it has acquired the domain along with the proprietary technology behind the project — a next-generation, AI-enhanced courthouse records platform. Together with Clerk Records founder and CEO Jason Smith, Energy Domain is developing two ways for users to access the technology: Energy Domain Courthouse, which will feature seamless integration into the user-friendly, cost-efficient Energy Domain Data tool, and an expanded, standalone platform. After decades shaping and guiding one of the leading courthouse data providers, Jason Smith launched Clerk Records earlier this year to pursue a more advanced, AI-driven vision. With this acquisition, Energy Domain gains not just his new technology, but also Smith himself in an advisory role — bringing with him the relationships and strategic insight needed to turn that technology into the next standard in courthouse data access. "A big part of collecting courthouse records is knowing how to work with hundreds of counties, understanding their formats and schedules, and having the personal relationships to actually get these documents," said Energy Domain CEO Ben Heinzelmann. "Once you've got the documents, though, it's all about the technology you use to index and integrate the data — and with Jason and Clerk Records, we're getting the best of both worlds." Smith expanded on that theme, explaining how recent advancements in AI are transforming what's possible (and newly affordable) across the market. "Up until very recently, extracting data from courthouse documents was almost entirely manual," Smith said. "If you wanted to pull attributes from an oil and gas lease, you were typing it all out, so companies could only afford to capture a handful of data points. With AI, we're pulling details from every page and every clause. That means our users can understand what the document actually says, and search on all those attributes." "An inflection point like this may not come around again in our careers," Smith continued. "I knew this was an unmissable opportunity to build something that leverages that kind of power from the ground up." With the technology in hand to extract the full range of courthouse data, both Smith and the Energy Domain leadership team saw the advantages of working together. Energy Domain Data already delivers proprietary rig tracking, well status, and production datasets through a user-friendly, map-based platform with flexible, transparent pricing. Adding Clerk Records' courthouse documents and mineral appraisal rolls brings new depth to the platform — helping Energy Domain deliver enterprise-grade intelligence in a format that's efficient, affordable, and built for real-world users. "This is about delivering what the market has been missing," Energy Domain COO Malcolm Smith said. "Land professionals, title researchers, and energy data teams have been stuck piecing together information from fragmented sources or paying enterprise-level prices for inflexible plans. Energy Domain is changing that. We're providing a single, powerful tool with transparent pricing, built for how research actually gets done." "We're preparing to launch Energy Domain Courthouse as a fully integrated companion to Energy Domain Data, while also expanding for users in real estate, legal, or surveying who prefer a standalone option," Heinzelmann concluded. "And we're not stopping there. We're currently indexing records from Texas, but we're looking to expand into New Mexico and Louisiana next. We're also developing tools that support common language search. That has always been a challenge in this space because of the inconsistent formats of courthouse documents across counties. But with structured AI extraction, we can finally build tools that reflect how people work — intuitive, complete, and available to everyone." To find out more about Energy Domain Data, visit to sign up for a free 7-day trial in your choice of basin. To receive updates on the upcoming availability of fully searchable courthouse records through Energy Domain Courthouse, contact sales@ ABOUT CLERK RECORDS, LLC Founded by courthouse data search pioneer Jason Smith, Clerk Records, LLC is building the next generation of courthouse records access, using AI-enhanced indexing and seamless API integration to help businesses access, analyze, and integrate land and mineral data into their operations. Visit for more information. ABOUT ENERGY DOMAIN Energy Domain has transformed into an upstream technology platform with two products — Energy Domain Marketplace and Energy Domain Data — to affordably, efficiently and synergistically serve their clients' needs. Born from a desire to revolutionize the oil and gas asset transaction process, Energy Domain began as a pioneering online marketplace fueled by data and driven by results. Having secured roughly $150MM in gross transaction volume under contract since 2021, Energy Domain Marketplace continues to empower both sellers and buyers with a streamlined platform, nationwide reach, and powerful analytics. Energy Domain Marketplace has now been joined by Energy Domain Data, an upstream intelligence platform designed to help oil and gas industry buyers and sellers underwrite assets and make informed decisions, with simplified data access, cost-effective flexibility and transparent pricing. Visit for more information. View source version on Contacts D'Arla Tyler DArla@ 817-405-9878 Sign in to access your portfolio
